Wall Street analysts predict that Thermo Fisher Scientific Inc. (NYSE:TMO) will announce earnings of $2.66 per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Thermo Fisher Scientific’s earnings, with estimates ranging from $2.60 to $2.75. Thermo Fisher Scientific posted earnings per share of $2.30 during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.7%. The company is scheduled to issue its next earnings results before the market opens on Wednesday, July 25th.

On average, analysts expect that Thermo Fisher Scientific will report full year earnings of $10.91 per share for the current year, with EPS estimates ranging from $10.88 to $10.97. For the next fiscal year, analysts expect that the company will report earnings of $12.14 per share, with EPS estimates ranging from $11.90 to $12.39. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 25th. The medical research company reported $2.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.08. The firm had revenue of $5.85 billion for the quarter, compared to analyst estimates of $5.62 billion. Thermo Fisher Scientific had a return on equity of 16.09% and a net margin of 10.24%. The company’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.08 earnings per share.

A number of analysts have recently commented on the company. ValuEngine lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, June 20th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $236.00 price target on the stock in a report on Thursday, May 17th. Finally, Morgan Stanley boosted their price target on Thermo Fisher Scientific from $216.00 to $230.00 and gave the company an “overweight” rating in a report on Thursday, April 26th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $226.33.

In related news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $212.00, for a total value of $530,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 45,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, June 15th. The shares were sold at an average price of $214.80, for a total value of $9,666,000.00. Following the completion of the sale, the chief executive officer now directly owns 315,122 shares in the company, valued at approximately $67,688,205.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 97,706 shares of company stock worth $21,125,673. 0.49% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in the stock. Viking Global Investors LP acquired a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $154,660,000. Millennium Management LLC increased its position in Thermo Fisher Scientific by 1,711.5% during the first quarter. Millennium Management LLC now owns 599,623 shares of the medical research company’s stock worth $123,798,000 after buying an additional 566,523 shares during the last quarter. Summit Trail Advisors LLC grew its position in shares of Thermo Fisher Scientific by 17,587.1% in the first quarter. Summit Trail Advisors LLC now owns 544,587 shares of the medical research company’s stock valued at $545,000 after purchasing an additional 541,508 shares during the last quarter. BlackRock Inc. grew its position in shares of Thermo Fisher Scientific by 2.0% in the first quarter. BlackRock Inc. now owns 24,582,453 shares of the medical research company’s stock valued at $5,075,294,000 after purchasing an additional 475,267 shares during the last quarter. Finally, Gofen & Glossberg LLC IL acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $67,593,000. 85.76% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific traded down $4.51, hitting $209.65, during midday trading on Friday, MarketBeat reports. 67,074 shares of the company’s stock were exchanged, compared to its average volume of 1,223,495. The firm has a market cap of $85.22 billion, a PE ratio of 22.10, a P/E/G ratio of 1.55 and a beta of 1.10. Thermo Fisher Scientific has a one year low of $170.07 and a one year high of $226.44. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69.

The business also recently announced a quarterly dividend, which will be paid on Monday, July 16th. Investors of record on Friday, June 15th will be given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date of this dividend is Thursday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 7.17%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.